Pretomanid
To view the entire topic, please log in or purchase a subscription.
Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
- Treatment of adults with pulmonary extensively drug-resistant (XDR) TB and treatment-intolerant or nonresponsive multidrug-resistant (MDR) TB in a combination regimen with bedaquiline and linezolid.
- Limitations of Use: Pretomanid is not indicated for patients with drug-sensitive TB, latent TB, extra-pulmonary infection due to M. tuberculosis, MDR-TB that is not treatment-intolerant or nonresponsive to standard therapy
- Safety and effectiveness have not been established in combination with drugs other than bedaquiline and linezolid.
-- To view the remaining sections of this topic, please log in or purchase a subscription --
INDICATIONS
FDA
- Treatment of adults with pulmonary extensively drug-resistant (XDR) TB and treatment-intolerant or nonresponsive multidrug-resistant (MDR) TB in a combination regimen with bedaquiline and linezolid.
- Limitations of Use: Pretomanid is not indicated for patients with drug-sensitive TB, latent TB, extra-pulmonary infection due to M. tuberculosis, MDR-TB that is not treatment-intolerant or nonresponsive to standard therapy
- Safety and effectiveness have not been established in combination with drugs other than bedaquiline and linezolid.
There's more to see -- the rest of this entry is available only to subscribers.